Publication: Topical ketorolac tromethamine in the reduction of adverse effects of laser in situ keratomileusis
Issued Date
2001-06-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-14344285337
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.84, No.6 (2001), 804-810
Suggested Citation
Panida Kosrirukvongs, Sabong Srivannaboon, Pinnita Prabhasawat, Kanograt Pornpanich Topical ketorolac tromethamine in the reduction of adverse effects of laser in situ keratomileusis. Journal of the Medical Association of Thailand. Vol.84, No.6 (2001), 804-810. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/26776
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Topical ketorolac tromethamine in the reduction of adverse effects of laser in situ keratomileusis
Other Contributor(s)
Abstract
Purpose: To evaluate whether topical ketorolac tromethamine can reduce the adverse effect of laser in situ keratomileusis (LASIK). Design: A prospective randomized controlled clinical study. Participants: Nineteen patients who underwent bilateral simultaneous LASIK performed at Siriraj Hospital. Intervention: Patients received two drops of ketorolac tromethamine in one eye immediately after surgery. Main Outcome Measures: Symptoms of tearing, photophobia, foreign body sensation and pain were evaluated at 30 minutes, 6 hours and 24 hours. Results: There was no statistically significant difference in symptoms at 30 minutes. At 6 and 24 hours, ketorolac-treated eyes had significantly fewer symptoms compared to non-treated eyes. Conclusions: Ketorolac tromethamine reduces some unfavorable symptoms within the first 24 hours after LASIK.